profit from every $100 of sales.
$0$100
Phreesia
$12.69+0.55% today
-43.7% in 1 year
1-year low $8.061-year high $22.53
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay $341.58 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Phreesia sold, what it kept, and what it did with the cash.
Sales went from $281 million in 2023 to $481 million in 2026, with $2.31 million of profit last year.
SalesProfit
Phreesia vs. similar companies
Phreesia grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Phreesia | 341.6× · Very expensive | ||
 GE HealthCare Technologies | 18.0× · Fair price | ||
 BrightSpring Health Services | 74.3× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.8× · Expensive |
AI analysis
An AI analyst reads Phreesia's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 281 | 356 | 420 | 481 | |
| 172 | 232 | 285 | 326 | |
| -177 | -136 | -58 | -7 | |
| -149 | -104 | -26 | 29 | |
| -176 | -137 | -59 | 2 | |
| -3.36 | -2.51 | -1.02 | 0.04 | |
| 61.1% | 65.2% | 67.9% | 67.9% | |
| -62.9% | -38.3% | -13.8% | -1.4% | |
| -62.7% | -38.4% | -13.9% | 0.5% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 370 | 370 | 388 | 664 |
| Cash | 177 | 88 | 84 | 74 |
| Total debt | 9 | 12 | 18 | 102 |
| Total liabilities | 82 | 119 | 124 | 327 |
| 288 | 251 | 265 | 337 | |
| 52 | 55 | 58 | 61 | |
| -46.4% | -40.0% | -14.9% | -0.4% | |
| -61.2% | -54.4% | -22.1% | 0.7% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| -90 | -32 | 32 | 79 | |
| 26 | 25 | 24 | 24 | |
| -116 | -57 | 8 | 54 | |
| Dividends paid | – | – | – | – |
| 19 | 12 | 0 | 0 | |
| 59 | 72 | 67 | 67 |
Valuation
- 341.6×
- 39.5×
- –
- 1.6×
- 1.6×
- 14.5×
- 27.7×
- 6.9%
- 0.3%
- 0.0%
Profitability
- 67.9%
- -1.4%
- 0.5%
- 6.1%
- 0.3%
- -31.7%
- 0.7%
- 0.3%
- -1.4%
- 25.3%
Growth
- +19.6%
- –
- +716.6%
- –
- +4.6%
Financial health
- 1.0×
- 0.30
- 15.4%
- -1.0×
- 1.53
- 1.53
- 0.72
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 34%of 952
Bottom 19%of 884
Bottom 1%of 601
Top 28%of 886
Top 14%of 987
What analysts expect
- Average price target
- $26.86
- Range
- $22.00 – $33.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 30, 2026 | 0.12 | 0.07 | +82.6% |
| Dec 8, 2025 | 0.10 | -0.00 | +27,877.8% |
| Sep 4, 2025 | 0.01 | -0.07 | +114.3% |
| May 28, 2025 | -0.07 | -0.13 | +46.2% |
| Mar 12, 2025 | -0.11 | -0.19 | +42.1% |
| Dec 9, 2024 | -0.25 | -0.27 | +7.4% |
| Sep 4, 2024 | -0.31 | -0.37 | +16.2% |
| May 30, 2024 | -0.35 | -0.51 | +31.4% |
News
Why Phreesia Stock Got Knocked Down TodayYahoo Finance · Sep 9, 2026The newest story we have is from Sep 9, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
41No pass
Benjamin Graham
45No pass
Philip Fisher
45No pass
Peter Lynch
66Pass
Joel Greenblatt
1No pass
Charlie Munger
27No pass
Terry Smith
35No pass
Questions about Phreesia
Is Phreesia a good stock to buy?
A business with weak numbers, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Phreesia AI analysis
What does Phreesia do?
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It is in Medical - Healthcare Information Services.
Does Phreesia pay a dividend?
No. Phreesia does not pay a dividend at the moment.
Is Phreesia stock halal?
Yes. Phreesia passes our halal screen: its business is permitted and its debt is 13% of its market value, under the 30% limit. How we check
How has Phreesia stock done over the past year?
Down 43.7% over the past twelve months, to $12.69. It traded between $8.06 and $22.53 and is 43.7% below its high.
Who are Phreesia's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with Phreesia's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.